198
Participants
Start Date
October 20, 2021
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2028
Isatuximab-Irfc 20 MG/ML [Sarclisa]
Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
Lenalidomide
"Induction: 25mg\*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~\*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) \< 50 mL/min) starting dose is 10 mg"
Dexamethasone Oral
"Induction:~Patients aged \<75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly"
Krankenhaus d. Barmh. Schwestern Wien, 1. Med. Abteilung, Onkologie und Hämatologie, Vienna
Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung, Vienna
Klinik Ottakring, 1.Med.Abt., Zentrum f. Onkologie, Haematologie und Palliativmedizin, Vienna
Univ.-Klinikum St. Pölten, Innere Medizin 1, Sankt Pölten
Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2, Mitterweng
PMU Salzburg: Universitätsklinik für Innere Medizin III, Salzburg
Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein
Krankenhaus Zams, Innere Medizin, Internistische Onkologie-Haematologie, Zams
LKH Hochsteiermark - Leoben, Abt. f. Innere Medizin, Haemato-Onkologie, Leoben
"General Hospital of Athens Evangelismos, Hematology Clinic", Athens
University Clinical Center of Serbia, Clinic for Hematology, Belgrade
"General Hospital of Athens Alexandra, Plasma Cell Dyscrasias Unit", Athens
University Clinical Center Kragujevac, Clinic for Hematology, Kragujevac
"Anticancer Hospital of Thessaloniki Theageneio, Hematology", Thessaloniki
Collaborators (1)
University of Navarra
OTHER
Medical University of Vienna
OTHER
Assign Data Management and Biostatistics GmbH
OTHER
WiSP GmbH
OTHER
Sanofi
INDUSTRY
Arbeitsgemeinschaft medikamentoese Tumortherapie
OTHER